Taiwan Stock Exchange · Basic Materials
CH Biotech R&D stock from India: price, numbers and tax
CH Biotech R&D (6534) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
CH Biotech R&D at a glance
- Price
- NT$90.80+NT$0.20 (0.22%)
- Market cap
- NT$9.15B
- Day range
- NT$90.10 – NT$91.40
- P/E
- 15.36
- Dividend yield
- 5.85%
- Volume
- 13.45K
- 1 month
- -0.77%
- 6 months
- -1.30%
- YTD
- +0.89%
- 1 year
- -18.93%
- 5 years
- —
CH Biotech R&D statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | NT$1.8B | NT$1.6B | NT$1.5B | NT$1.4B | NT$1.0B |
| Gross profit | NT$1.4B | NT$1.4B | NT$1.3B | NT$1.1B | NT$847.9M |
| Operating income | NT$623.1M | NT$542.3M | NT$565.9M | NT$582.0M | NT$373.4M |
| Net income | NT$463.8M | NT$476.4M | NT$463.3M | NT$465.4M | NT$291.5M |
| Earnings per share | NT$4.51 | NT$4.61 | NT$4.76 | NT$4.79 | NT$3.00 |
| EBITDA | NT$837.3M | NT$797.7M | NT$761.6M | NT$722.3M | NT$470.2M |
| Total assets | NT$3.6B | NT$3.6B | NT$3.6B | NT$3.2B | NT$3.0B |
| Total debt | NT$664.3M | NT$747.3M | NT$845.2M | NT$894.9M | NT$1.1B |
| Cash and short-term investments | NT$397.3M | NT$482.1M | NT$943.0M | NT$533.1M | NT$326.8M |
| Shareholders' equity | NT$2.7B | NT$2.6B | NT$2.5B | NT$2.1B | NT$1.7B |
| Operating cash flow | NT$589.0M | NT$538.4M | NT$659.2M | NT$699.0M | NT$264.4M |
| Free cash flow | NT$465.7M | −NT$51.5M | NT$542.9M | NT$581.4M | NT$192.4M |
| Capital expenditure | −NT$123.3M | −NT$590.0M | −NT$116.3M | −NT$117.6M | −NT$71.9M |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in TWD; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| TSRC | 2103.TW | NT$27.95 | NT$23.08B |
| Grand Pacific Petrochemical | 1312.TW | NT$14.60 | NT$16.16B |
| Oriental Union Chemical | 1710.TW | NT$17.00 | NT$14.91B |
| Nantex Industry | 2108.TW | NT$28.35 | NT$13.96B |
| USI | 1304.TW | NT$12.45 | NT$13.35B |
| YC Inox | 2034.TW | NT$23.60 | NT$12.48B |
| San Fu Chemical | 4755.TW | NT$119.00 | NT$11.98B |
| International CSRC Investment | 2104.TW | NT$11.00 | NT$10.67B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in CH Biotech R&D from India
What CH Biotech R&D does
CH Biotech R&D Co., Ltd. is a company dedicated to the creation and worldwide supply of agricultural chemicals rooted in biotechnology. Their commercial footprint spans Taiwan, the United States, Canada, Australia, Brazil, Argentina, Uruguay, and Chile, in addition to other international markets. CH Biotech R&D operates in the Agricultural Inputs industry within the Basic Materials sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell CH Biotech R&D shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the TWD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.